Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 62
Filter
1.
Clin Pathol ; 16: 2632010X231183693, 2023.
Article in English | MEDLINE | ID: mdl-37534372

ABSTRACT

Aims: To assess the impact of the molecular subtype (MS) on the total number of CK19 mRNA copies in all positive SLN (TTL) threshold, to predict non-SLN affectation, and to compare 5 years progression-free survival (PFS) according to the risk of recurrence (ROR) group by PAM50. Methods: Cohort with infiltrating breast cancer with intra-operative metastatic SLN detected by one-step nucleic acid amplification (OSNA) assay who underwent subsequent ALND. Logistic regression was used to assess a possible interaction between TTL and MS(Triple Negative, Her-2-Enriched, Luminal A, or Luminal B), or hormone receptors (HR: positive or negative) by immunohistochemistry (IMH). Cox regression was used to compare PFS and OS in the 3 ROR groups (high, medium, or low). Results: TTL was predictive of non-SLN affectation in both univariate (OR [95% CI]: 1.72 [1.43, 2.05], P < .001) and multivariate (1.55 [95% CI: 1.04, 2.32], P = .030) models, but MS-IMH or HR-IMH, and their interactions with TTL were not (best multivariate model: HR + main effect OR 1.16 [95% CI: 0.18, 7.64], P = .874; interaction OR: 1.04 [0.7, 1.55], P = .835; univariate model: HR + main effect OR: 1.44 [95% CI: 0.85, 2.44], P = .180). PFS was lower in the high-risk ROR group (81.1%) than in the low-risk group (93.9%) (HR: 3.68 [95 CI: 1.70, 7.94], P < .001). Conclusions: our results do not provide evidence to support the utilization of subtype-specific thresholds for TTL values to make therapeutic decisions on the axilla. The ROR group was predictive of 5 years-PFS.

2.
Clin. transl. oncol. (Print) ; 23(3): 536-542, mar. 2021.
Article in English | IBECS | ID: ibc-220888

ABSTRACT

Purpose Treatment of recurrent ovarian carcinoma is a challenge, particularly for the clear cell (CCC) subtype. However, there is a preclinical rationale that these patients could achieve a benefit from antiangiogenic therapy. To assess this hypothesis, we used the growth modulation index (GMI), which represents an intrapatient comparison of two successive progression-free survival (PFS). Methods We conducted a retrospective real-world study performed on 34 patients with recurrent ovarian cancer, treated with bevacizumab-containing regimens from January 2009 to December 2017. The primary endpoint was GMI. An established cut-off > 1.33 was defined as a sign of drug activity. Results 73.5% of patients had high-grade serous ovarian carcinoma (HGSOC), and 17.7% had CCC; 70.6% of patients received carboplatin/gemcitabine/bevacizumab, and 29.4% received weekly paclitaxel/bevacizumab. According to histological subtype, the overall response rate and median PFS were 52% and 14 months for HGSOC and 83.3% and 20 months for CCC, respectively. The overall population median GMI was 0.99; it was 0.95 and 2.36 for HGSOC and CCC, respectively. CCC subtype was significantly correlated with GMI > 1.33 (odds ratio 41.67; 95% confidence interval 3.6–486.94; p = .03). Conclusion Adding bevacizumab to chemotherapy in recurrent CCC is associated with a remarkable benefit in this cohort. The efficacy of antiangiogenic drugs in CCC warrants further prospective evaluation (AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Adenocarcinoma, Clear Cell/drug therapy , Ovarian Neoplasms/drug therapy , Bevacizumab/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Angiogenesis Inhibitors/therapeutic use , Neoplasm Recurrence, Local , Treatment Outcome
3.
Clin Transl Oncol ; 23(3): 536-542, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32651885

ABSTRACT

PURPOSE: Treatment of recurrent ovarian carcinoma is a challenge, particularly for the clear cell (CCC) subtype. However, there is a preclinical rationale that these patients could achieve a benefit from antiangiogenic therapy. To assess this hypothesis, we used the growth modulation index (GMI), which represents an intrapatient comparison of two successive progression-free survival (PFS). METHODS: We conducted a retrospective real-world study performed on 34 patients with recurrent ovarian cancer, treated with bevacizumab-containing regimens from January 2009 to December 2017. The primary endpoint was GMI. An established cut-off > 1.33 was defined as a sign of drug activity. RESULTS: 73.5% of patients had high-grade serous ovarian carcinoma (HGSOC), and 17.7% had CCC; 70.6% of patients received carboplatin/gemcitabine/bevacizumab, and 29.4% received weekly paclitaxel/bevacizumab. According to histological subtype, the overall response rate and median PFS were 52% and 14 months for HGSOC and 83.3% and 20 months for CCC, respectively. The overall population median GMI was 0.99; it was 0.95 and 2.36 for HGSOC and CCC, respectively. CCC subtype was significantly correlated with GMI > 1.33 (odds ratio 41.67; 95% confidence interval 3.6-486.94; p = .03). CONCLUSION: Adding bevacizumab to chemotherapy in recurrent CCC is associated with a remarkable benefit in this cohort. The efficacy of antiangiogenic drugs in CCC warrants further prospective evaluation.


Subject(s)
Adenocarcinoma, Clear Cell/drug therapy , Angiogenesis Inhibitors/therapeutic use , Bevacizumab/therapeutic use , Cystadenocarcinoma, Serous/drug therapy , Neoplasm Recurrence, Local/drug therapy , Ovarian Neoplasms/drug therapy , Adenocarcinoma, Clear Cell/mortality , Adenocarcinoma, Clear Cell/pathology , Adult , Aged , Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/therapeutic use , Confidence Intervals , Cystadenocarcinoma, Serous/mortality , Cystadenocarcinoma, Serous/pathology , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Female , Humans , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Odds Ratio , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Paclitaxel/therapeutic use , Progression-Free Survival , Retrospective Studies , Gemcitabine
4.
Ann R Coll Surg Engl ; 101(3): 186-192, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30421628

ABSTRACT

INTRODUCTION: Recent prospective studies support the feasibility of performing sentinel lymph node biopsy following neoadjuvant chemotherapy in initially fine-needle aspiration cytology or ultrasound-guided biopsy-proven node-positive breast cancer. The main aid is to identify preoperative features that help us predict a complete axillary response to neoadjuvant chemotherapy in these patients and thus select the candidates for sentinel lymph node biopsy post-neoadjuvant chemotherapy to avoid unnecessary axillary lymphadenectomy. MATERIALS AND METHODS: A retrospective observational study with a total of 150 patients, biopsy-proven node-positive breast cancer who underwent neoadjuvant chemotherapy followed by breast surgery and axillary lymphadenectomy were included and retrospectively analysed. A predictive model was generated by a multivariate logistic regression analysis for pathological complete response-dependent variable. RESULTS: The response of the primary lesion to neoadjuvant chemotherapy according to post-treatment magnetic resonance imaging, Her2/neu overexpression and a low estrogen receptor expression are associated with a higher rate of nodal pathologically complete response. The multivariant model generated a receiver operating characteristic curve with an area under the curve of 0.79 and a confidence interval of 0.72-0.87 at a 95% level of significance. CONCLUSIONS: This model could be a helpful tool for the surgeon to help in predicting which cases have a higher likelihood of achieving a pathologically complete response and therefore selecting those who may benefit from a post-neoadjuvant chemotherapy sentinel lymph node biopsy and avoid unnecessary axillary lymphadenectomy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/therapy , Lymphatic Metastasis/diagnosis , Mastectomy/methods , Sentinel Lymph Node/surgery , Adult , Aged , Aged, 80 and over , Axilla , Biopsy, Fine-Needle , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/pathology , Female , Humans , Lymph Node Excision/methods , Lymph Node Excision/statistics & numerical data , Lymphatic Metastasis/pathology , Magnetic Resonance Imaging , Mastectomy/statistics & numerical data , Middle Aged , Models, Biological , Neoadjuvant Therapy/methods , Neoplasm Grading , Neoplasm Staging , Patient Selection , Prognosis , Retrospective Studies , Sentinel Lymph Node/diagnostic imaging , Sentinel Lymph Node/pathology , Sentinel Lymph Node Biopsy/methods , Treatment Outcome
5.
Clin. transl. oncol. (Print) ; 20(3): 274-285, mar. 2018. tab
Article in English | IBECS | ID: ibc-171314

ABSTRACT

Because of advances in the understanding of histological and molecular characteristics in ovarian cancer, it is now possible to recognize the existence of five subtypes, which in turn has allowed a more refined therapeutic approach and better design of clinical trials. Each of these five subtypes has specific histological features and a particular biomarker expression, as well as mutations in different genes, some of which have prognostic and predictive value. CA125 and HE4 are examples of ovarian cancer biomarkers used in the diagnosis and follow-up of these malignancies. Currently, somatic or germinal mutations on BRCA1 and BRCA2 genes are the most important biomarkers in epithelial ovarian cancer having prognostic and predictive value. This article will review the histological and molecular characteristics of the five subtypes of ovarian cancer, describing the most important biomarkers and mutations that can guide in diagnosis, screening and tailored treatment strategy (AU)


No disponible


Subject(s)
Humans , Female , Ovarian Neoplasms/pathology , Tumor Suppressor Proteins/analysis , Biomarkers, Tumor/analysis , Genetic Markers , Mutation/genetics , Early Detection of Cancer
6.
Clin Transl Oncol ; 20(3): 274-285, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28815456

ABSTRACT

Because of advances in the understanding of histological and molecular characteristics in ovarian cancer, it is now possible to recognize the existence of five subtypes, which in turn has allowed a more refined therapeutic approach and better design of clinical trials. Each of these five subtypes has specific histological features and a particular biomarker expression, as well as mutations in different genes, some of which have prognostic and predictive value. CA125 and HE4 are examples of ovarian cancer biomarkers used in the diagnosis and follow-up of these malignancies. Currently, somatic or germinal mutations on BRCA1 and BRCA2 genes are the most important biomarkers in epithelial ovarian cancer having prognostic and predictive value. This article will review the histological and molecular characteristics of the five subtypes of ovarian cancer, describing the most important biomarkers and mutations that can guide in diagnosis, screening and tailored treatment strategy.


Subject(s)
Biomarkers, Tumor/analysis , Neoplasms, Glandular and Epithelial/diagnosis , Ovarian Neoplasms/diagnosis , Carcinoma, Ovarian Epithelial , Female , Humans
8.
Acta Trop ; 164: 360-368, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27686961

ABSTRACT

American trypanosomiasis has long been a neglected disease endemic in LatinAmerica, but congenital transmission has now spread Chagas disease to cause a global health problem. As the early stages of the infection of placental tissue and the vertical transmission by Trypanosoma cruzi are still not well understood, it is important to investigate the relevance of the first structure of the placental barrier in chorionic villi infection by T. cruzi during the initial stage of the infection. Explants of human chorionic villi from healthy pregnant women at term were denuded of their syncytiotrophoblast and co-cultured for 3h, 24h and 96h with 800,000 trypomastigotes (simulating acute infection). T. cruzi infected cells were identified by immunohistochemistry for cytokeratin-7 (+cytotrophoblast) and CD68 (+macrophages), and the infection was quantified. In placental tissue, the parasite load was analyzed by qPCR and microscopy, and the motile trypomastigotes were quantified in culture supernatant. In denuded chorionic villous, the total area occupied by the parasite (451.23µm2, 1.33%) and parasite load (RQ: 87) was significantly higher (p<0.05) than in the entire villous (control) (5.98µm2, 0.016%) (RQ:1) and with smaller concentration of nitric oxide. Stromal non-macrophage cells were infected as well as cytotrophoblasts and some macrophages, but with significant differences being observed. The parasite quantity in the culture supernatant was significantly higher (p<0.05) in denuded culture explants from 96h of culture. Although the human complete chorionic villi limited the infection, the detachment of the first structure of the placenta barrier (syncytiotrophoblast) increased both the infection of the villous stroma and the living trypomastigotes in the culture supernatant. Therefore structural and functional alterations to chorionic villi placental barrier reduce placental defenses and may contribute to the vertical transmission of Chagas.


Subject(s)
Chagas Disease/transmission , Chorionic Villi/parasitology , Infectious Disease Transmission, Vertical , Trypanosoma cruzi/metabolism , Antigens, CD/immunology , Antigens, Differentiation, Myelomonocytic/immunology , Coculture Techniques , Female , Humans , Keratin-7/immunology , Nitric Oxide , Placenta/parasitology , Polymerase Chain Reaction , Pregnancy
9.
Br J Cancer ; 110(4): 1088-100, 2014 Feb 18.
Article in English | MEDLINE | ID: mdl-24548884

ABSTRACT

BACKGROUND: Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast Cancer Association Consortium. METHODS: Data were combined from 49 studies, including 53 835 cases and 50 156 controls, of which 89 050 (46 450 cases and 42 600 controls) were of European ancestry, 12 893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression. RESULTS: Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95% confidence interval=1.02-1.09, P=0.0020), which is substantially lower than that observed for SNPs in FGFR2. CONCLUSION: Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree observed for FGFR2.


Subject(s)
Breast Neoplasms/genetics , Genetic Predisposition to Disease , Receptor, Fibroblast Growth Factor, Type 2/genetics , Case-Control Studies , Female , Genetic Variation , Genome-Wide Association Study , Genotype , Humans , Polymorphism, Single Nucleotide/genetics , Receptor, Fibroblast Growth Factor, Type 1/genetics , Receptor, Fibroblast Growth Factor, Type 3/genetics , Receptor, Fibroblast Growth Factor, Type 4/genetics , Receptor, Fibroblast Growth Factor, Type 5/genetics
10.
Anat Rec (Hoboken) ; 293(12): 2144-6, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21077176

ABSTRACT

The purpose of this study was to obtain a mathematical formula to calculate the tonsillar volume out of its measurements assessed on surgical specimens. Thirty consecutive surgical specimens of pediatric tonsils were studied. The maximum lengths ("a"), widths ("b"), and depths ("c") of the dissected specimens were measured in millimeters, and the volume of each tonsil was measured in milliliters. One-sample Kolmogorov-Smirnov test was used to check the normality of the sample. To calculate the reproducibility of the quantitative variables, intraclass correlation coefficients were used. Two formulas with high reproducibility (coefficient R between 0.75 and 1) were obtained: 1) [a*b*c* 0.5236] with R = 0.8688; and 2) [a*b*b* 0.3428] with R = 0.9073. It is possible to calculate the volume of the palatine tonsils in surgical specimens precisely enough based on their three measures, or their two main measures (length and width).


Subject(s)
Anthropometry/methods , Palatine Tonsil/pathology , Algorithms , Child , Humans , Hypertrophy/pathology , Organ Size
11.
Gynecol Oncol ; 118(1): 88-92, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20439111

ABSTRACT

Ovarian cancer is the second most common gynecologic malignancy, and represents the fifth most common cause of cancer death in women in the United States. The age at diagnosis, extent of disease, success of primary surgery, and the histopathological features of the tumor are important prognostic markers. Epithelial ovarian carcinomas are classified into four major categories: serous, mucinous, endometrioid, and clear cell. Each subtypes of ovarian carcinoma are known to have different clinical characteristics and biological behaviour and response to chemotherapy. Molecular studies have supported for the notion that the different histological types of ovarian cancer likely represent histopathologically, genetically, and biologically distinct diseases. Microarray-based profiling technologies have provided an opportunity to simultaneously examine the relationship between thousands of genes and clinical phenotypes. In this review, we will summarise the current gene-expression profiles that address the classification of ovarian cancer into molecular subtypes with different outcomes.


Subject(s)
Ovarian Neoplasms/genetics , Female , Gene Expression Profiling , Humans , Ovarian Neoplasms/pathology
12.
Clin. transl. oncol. (Print) ; 11(9): 564-571, sept. 2009. ilus
Article in English | IBECS | ID: ibc-123678

ABSTRACT

Ovarian carcinoma is the most important cause of gynaecological cancer-related mortality in Western societies. The age at diagnosis, extent of disease (as expressed by FIGO state), success of primary surgery and the histopathological features of the tumour are important prognostic markers. The majority of patients with ovarian cancer present with advanced disease (FIGO stage III/IV) and in this group of patients the median survival is only three years. New treatment approaches are therefore required to improve outcome in this disease. Angiogenesis, the development of a neovascular blood supply, is a critical step in the propagation of malignant tumour growth and metastasis and represents a promising target. This review will focus on angiogenesis, VEGF biology and the potential value of angiogenic factors with prognostic value in ovarian cancer (AU)


Subject(s)
Humans , Female , Carcinoma/blood supply , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/genetics , Prognosis , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Neovascularization, Pathologic/physiopathology , Ovarian Neoplasms/blood supply , Ovary/blood supply , Vascular Endothelial Growth Factor Receptor-1/genetics , Vascular Endothelial Growth Factor Receptor-1/physiology , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Carcinoma/genetics , Models, Biological , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/pathology , Neovascularization, Physiologic/genetics , Neovascularization, Physiologic/physiology , Nitric Oxide Synthase Type II/genetics , Ovarian Neoplasms/pathology
13.
J Pathol ; 215(3): 231-44, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18473330

ABSTRACT

Pleomorphic lobular carcinomas (PLC) of the breast display histological features associated with classic invasive lobular carcinoma (ILC), yet they also exhibit more conspicuous nuclear atypia and pleomorphism, and an aggressive clinical behaviour. From a breast cancer progression perspective, it is unclear whether PLC is a variant of ILC or is a high-grade invasive ductal carcinoma (IDC) that has lost E-cadherin. The molecular features of 26 PLC were studied using immunohistochemistry [oestrogen receptor (ER), progesterone receptor (PR), HER2, p53 and E-cadherin], 0.9 Mb resolution, microarray-based comparative genomic hybridization (aCGH), fluorescent (FISH) and chromogenic (CISH) in situ hybridization and loss of heterozygosity. Comparative analysis was performed with aCGH data from PLC with classic ILC (16 cases) and high grade IDC (35 cases). PLCs were frequently ER- and PR-positive, E-cadherin-negative and occasionally HER2- and p53-positive. Recurrent copy number changes identified by aCGH included gains on 1q, 8q, 11q, 12q, 16p and 17q and losses on 8p, 11q, 13q, 16q and Xq. Highly recurrent 1q+ (100% of cases), 16p+ (93%), 11q- (53%) and 16q- (93%) and evidence of the der(1;16)/der(16)t(1;16) rearrangement, as detected by FISH, suggested that PLC had a 'lobular genotype'. Focal amplifications were evident at 8p12-p11, 8q24, 11q13.1-q14.1, 12q14, 17q12 and 20q13. Loss of BRCA2 was detected in 40% of PLC by LOH. Comparative analysis of aCGH data suggested the molecular features of PLC (ER/PR-positive, E-cadherin-negative, 1q+, 11q(-), 16p+ and 16q(-)) were more closely related to those of ILC than IDC, implicating an overlapping developmental pathway for these lobular tumour types. Molecular alterations found in PLC that are more typical of high-grade IDC than ILC (p53 and HER2 positivity, 8q+, 17q24-q25+, 13q(-) and amplification of 8q24, 12q14, 17q12 and 20q13) are likely to drive the high-grade and more aggressive biology of PLC.


Subject(s)
Breast Neoplasms/genetics , Carcinoma, Lobular/genetics , Gene Expression Regulation, Neoplastic , Biomarkers, Tumor/analysis , Breast Neoplasms/chemistry , Carcinoma, Ductal, Breast/chemistry , Carcinoma, Ductal, Breast/genetics , Carcinoma, Lobular/chemistry , Female , Gene Expression Profiling , Humans , Immunohistochemistry , In Situ Hybridization , Loss of Heterozygosity , Oligonucleotide Array Sequence Analysis
14.
Eur J Obstet Gynecol Reprod Biol ; 137(2): 222-6, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17481802

ABSTRACT

OBJECTIVE: Pure squamous cell carcinoma (SCC) of the breast is a rare tumour and its clinical behaviour is not correctly known. The aim of the study is to evaluate the prevalence, epidemiological and clinical characteristics of the cases of SCC studied in our institution. STUDY DESIGN: The breast department's database was searched for patients diagnosed with breast SCC between September 1979 and June 2006. Pathological features, outcome aspects and prognosis were studied. All specimens were reviewed by our pathologist who performed inmunohistochemistry for hormone receptors. RESULTS: Eleven patients were identified (0.19%) between 5771 cases of breast cancer. Mean age was 64 (37-76) years and mean follow-up was 46 (6-216) months. Mean disease free survival (DFS) was 92 months (S.E.=33), with a 36% DFS rate at 5 years and the mean overall survival was 93 months (S.E.=34). Mean survival from the time recurrent disease was recognized was 9 (1-16) months. Tumours were hormone receptor negative. CONCLUSIONS: SCC of the breast is aggressive and often treatment-refractory. The role of different new chemotherapy regimens need to be explored.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/therapy , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/therapy , Adult , Aged , Breast Neoplasms/pathology , Carcinoma, Squamous Cell/pathology , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Humans , Mastectomy , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Prevalence , Prognosis , Radiotherapy, Adjuvant , Retrospective Studies , Survival Analysis , Treatment Outcome
15.
Free Radic Res ; 41(6): 681-7, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17516241

ABSTRACT

Phospholipid Hydroperoxide Glutathione Peroxidase (PHGPx) is the only known enzyme able to reduce lipid peroxides bound to cell membranes. Moreover it has been involved in apoptosis and can influence intracellular signaling. To investigate the possible relationship between PHGPx and human cancer we have quantified PHGPx expression levels by real-time quantitative PCR and immunohistochemistry in tissue samples of human breast invasive ductal carcinoma from 34 patients compared with their own controls of benign breast tissue. PHGPx expression levels were compared with the clinical and pathological data of these patients. The results showed that PHGPx expression levels are downregulated in poorly differentiated (grade 3) breast invasive ductal carcinoma (P = 0.0043). PHGPx expression levels decreased gradually with tumor grade from grade 1 to grade 3. We also found a downregulation of PHGPx in cases that showed p53 accumulation compared with cases without p53 immunostaining (P = 0.0011). PHGPx was also downregulated in cases without progesterone receptors (PR) immunostaining compared with cases with PR immunostaining (P = 0.0165). Grade 3, p53 immunostaining and absence of PR immunostaining are poor prognostic factors. These results suggest that PHGPx downregulation could be related with a poorer prognosis in breast invasive ductal carcinoma.


Subject(s)
Breast Neoplasms/enzymology , Carcinoma, Ductal, Breast/enzymology , Cell Differentiation , Gene Expression Regulation, Enzymologic , Glutathione Peroxidase/metabolism , Adult , Aged , Biomarkers, Tumor/metabolism , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/genetics , Carcinoma, Ductal, Breast/pathology , Down-Regulation , Female , Glutathione Peroxidase/genetics , Humans , Immunoenzyme Techniques , Middle Aged , Phospholipid Hydroperoxide Glutathione Peroxidase , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Neoplasm/genetics , RNA, Neoplasm/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tumor Suppressor Protein p53/metabolism
16.
J Clin Oncol ; 23(29): 7278-85, 2005 Oct 10.
Article in English | MEDLINE | ID: mdl-16129846

ABSTRACT

PURPOSE: We sought to reproduce with quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) the results obtained with a 70-gene expression profile that has been described previously in breast cancer. PATIENTS AND METHODS: Frozen breast cancer samples from patients who were operated on were used to isolate tumor RNA. Ninety-six patients with stage I to II disease were included. Median age was 57 years (range, 27 to 80 years). Forty-eight patients had lymph node-negative and 48 lymph node-positive disease. qRT-PCR amplifications were performed and the results were correlated with clinical data. RESULTS: After a minimum follow-up of 5 years, 25 patients had a relapse. The gene profile divided patients into two groups with poor and good prognosis. Significant differences with regard to grade of differentiation, size and hormone receptors were seen between the two groups. The gene profile was significantly associated with relapse-free survival and overall survival in the whole group of 96 patients. Multivariate analysis showed that only lymph node status and gene profile were significantly correlated to overall survival. CONCLUSION: qRT-PCR reproduced the results obtained with microarrays for a prognostic gene profile in women with early-stage breast cancer.


Subject(s)
Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , Carcinoma, Lobular/genetics , Gene Expression Profiling/methods , Adult , Aged , Aged, 80 and over , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/pathology , Female , Humans , Middle Aged , Neoplasm Staging , Prognosis , Reverse Transcriptase Polymerase Chain Reaction
17.
Clin Transl Oncol ; 7(6): 239-43, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16131446

ABSTRACT

INTRODUCTION: A number of findings suggest that cyclooxygenase-2 (COX-2) is overexpressed in breast tumours. However, there is a lack of consensus in the literature regarding the pattern of expression of this protein in invasive breast ductal carcinoma and in the adjacent non-tumour ductal epithelium. This study compares the expression of COX-2 mRNA and protein in breast ductal carcinoma relative to non-tumour breast tissue. MATERIAL AND METHODS: We analysed the expression of COX-2 mRNA by quantitative PCR, and COX-2 protein by immunohistochemistry in invasive ductal carcinoma as well as in non-tumour adjacent ductal epithelium from 34 breast biopsies diagnosed as being invasive ductal carcinoma. As control, we analysed expression of COX-2 protein by immunohistochemistry in surgically-resected benign breast lesions. RESULTS: Our results show that COX-2 mRNA and protein are overexpressed in non-tumour ductal epithelium compared with invasive ductal carcinoma. However, the pattern of the protein expression is different in tumour and non-tumour tissue: COX-2 protein is expressed predominantly in the membrane of the non-tumour ductal epithelium (including in benign breast lesions) while, in invasive ductal carcinoma cells, it is localised in the cytoplasm. CONCLUSIONS: The non-tumour ductal epithelium adjacent to invasive ductal carcinoma shows a higher COX-2 expression than does the invasive ductal carcinoma. However, the different localisation of the immunohistochemically-detected protein suggests a possible post-translational regulation of the protein.


Subject(s)
Breast Neoplasms/metabolism , Breast/metabolism , Carcinoma, Ductal, Breast/metabolism , Adult , Aged , Breast/pathology , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Epithelium/metabolism , Epithelium/pathology , Female , Humans , Immunohistochemistry , Middle Aged , Polymerase Chain Reaction , RNA, Messenger/analysis
18.
Prog. obstet. ginecol. (Ed. impr.) ; 48(9): 448-452, sept. 2005. ilus
Article in Es | IBECS | ID: ibc-040810

ABSTRACT

El tumor de células de Leydig de ovario es un tipo de neoplasia muy raro que suele presentarse en mujeres posmenopáusicas. Presentamos el caso de una mujer de 72 años que consultó por virilización. Las determinaciones hormonales mostraron una elevación muy marcada de la testosterona (12.038 pg/ml), con valores normales del resto de hormonas sexuales. En la ecografía se observó una tumoración de 10 mm en el ovario izquierdo. Se realizó histerectomía y doble anexectomía. El estudio histológico demostró la existencia de un tumor de células de Leydig en el ovario izquierdo. Tras la intervención, los valores plasmáticos de testosterona se normalizaron, y la paciente mostró una lenta regresión de los síntomas clínicos


Leydig cell tumor of the ovary is a very rare neoplasm that usually occurs in postmenopausal women. We report the case of a 72-year-old woman with symptoms of virilization. Hormonal evaluation showed marked elevation of serum testosterone (12038 pg/ml) and no evidence of increased production of other sexual hormones. Ultrasound examination revealed a 10-mm tumor within the left ovary. Subsequently, total hysterectomy with bilateral oophorectomy was performed. Histopathological examination showed a Leydig cell tumor within the left ovary. Postoperative plasma testosterone levels returned to normal and the patient showed slow regression of clinical symptoms


Subject(s)
Female , Aged , Humans , Leydig Cell Tumor/complications , Virilism/etiology , Ovarian Neoplasms/complications , Leydig Cell Tumor/pathology , Postmenopause , Virilism/pathology , Testosterone/analysis , Ovarian Neoplasms/pathology
19.
Cytopathology ; 15(6): 321-5, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15606365

ABSTRACT

Carcinoma with osteoclast-like giant cells (OCGC) is an uncommon neoplasm characterized by giant cells, prominent vascularization, haemorrhage and areas of cribriform epithelial growth with moderate atypia. Multinucleated giant cells (MGC) have been described in several other breast lesions raising an interesting differential diagnosis, mainly with benign disorders. Due to its rarity few cases have been described cytologically. We retrospectively reviewed 13 fine needle aspiration samples from nine patients with this variant of carcinoma. Nine corresponded to breast tumours and four to axillary, liver, subcutaneous and mediastinal metastatic lesions. The expression of CD68 by giant cells was evaluated immunocytochemically in six cases. All patients had a complete pathological study of the breast neoplasm. Smears showed a double component of epithelial and giant cells. Epithelial clusters were predominantly of intermediate size with irregular contours. Most were cohesive but others showed cellular dissociation with scarce to moderate cellular pleomorphism. Giant cells had well defined, deeply stained cytoplasm and round to elongated morphology. Two metastatic cases were devoid of them. Haemosiderin-laden macrophages were common in smears from breast tumours. In the six cases tested CD68 was expressed in MGC. Cytological features of mammary carcinoma with OCGC correlate closely with the histological ones. Most cases are clearly recognizable as malignant but in others cytological atypia may be minimal, mimicking a benign lesion. In difficult cases the presence of haemosiderin-laden macrophages and the histiocytic nature of the MGC are helpful diagnostic features.


Subject(s)
Breast Neoplasms/diagnosis , Giant Cells/pathology , Osteoclasts/pathology , Adult , Aged , Aged, 80 and over , Antigens, CD/analysis , Antigens, CD34/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Biopsy, Fine-Needle , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carcinoma, Ductal/pathology , Carcinoma, Lobular/pathology , Cytodiagnosis/methods , Female , Giant Cells/chemistry , Hemosiderin/analysis , Humans , Keratins/analysis , Macrophages/chemistry , Macrophages/pathology , Middle Aged , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...